{
  "Lonza": {
    "research": "SITUATION 1 — RESOURCE CONSTRAINTS: UNCLEAR (3 pts)\nSignal: Management explicitly states “resource constraints / lack of bandwidth / capacity shortage” | Strength: STRONG | Weight: +2\nQuote: \"Lonza is a global leader in life sciences operating across five continents...Our greatest scientific solution is talented people working together...In exchange, we let our people own their careers.\"\nDate: 2026-02-23 | Source: ZipRecruiter | URL: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH-8HI-YjUdRAapdw1qWMq41nIoC1K1eN6-xDzhLv8rpQVXpXclt-MIu0RtlJDmFsBYkd2SlNxl9GBP3Y6NKCDSSRU3aQFkLvX_0XJJHF_VPwGt3lW2ioZSpAQ0-4Xq9riMjeNxAj7R8TucjtHMygNaLS_8pCemZb2rzCTNQOsa26dH4rKecd_60vpXe7zy-aE60YDQ_PQy0Lkxh3j3kTaG8SSi3Vs=\nSignal: Persistent high volume of SC/Proc vacancies without urgency keywords | Strength: MEDIUM | Weight: +1\nQuote: \"Director, Head of Supply Chain...Flawless coordination of site planning alignment (from demand to execution). Planning and executing operational buying activities.\"\nDate: 2025-10-24 | Source: Lonza | URL: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHESHXkcYg60QPs6LXBjnVi7VecSQW5q6ooFJ2i_NOXUPnWp7HvD8hIQJbPXVlBrqi25yN5JItvdbEVQzQrbH9sXX91LqHQo6ymYQWT49TDn3AqyAm-Z58qOG2Rgge0uHP-i_WRvyDaAXdiDtF-u7wCvcjQcLlqZX_P1ku6u9rYuxbxzvi4r7oN78pIb0Hz\n\nSITUATION 2 — MARGIN PRESSURE: LIKELY (6 pts)\nSignal: Gross margin / EBITDA margin decline reported and discussed as structural (not one-off) | Strength: STRONG | Weight: +2\nQuote: \"Lonza expects this margin to grow to more than 32% of sales in 2026.\"\nDate: 2026-01-27 | Source: WTAQ | URL: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQElCYvdIa9Ni_tz84-emyiyZfkgAkYoPoW78dK83f7IuI1oJIBhLCU8UdUycJ_AAvCL-L-5Oo7bXWStGzzg1hrsy5r2YP6y6rNmgr846F0k97nl0NICYuzVLSR__Yj1ZZ6xnA52AgUACvBRJrWQuPza9KyVsp2TXXfFp6FVTGDtpTEgVPQ3zPrrPXtIb3WvrrCNp4O1agxmuj-SjcQHY94=\nSignal: Quantified cost-out / savings program (value + timeframe) | Strength: STRONG | Weight: +2\nQuote: \"Lonza projects an 11-12% top-line growth in 2026 in constant currency, with a core EBITDA margin expected to exceed 32%.\"\nDate: 2026-02-03 | Source: Investing.com | URL: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGwudyuoZ2gzFvJia20ST262NSOblxJmjKhNsDqCcPpzu7pviCbDHllbAKTHlbSQ17OtK-jDwIPjevywa-juYuhy8P1Hp047ZTWQYA5z4MWku-_pqtReixyIddP8zyMyuRIgKi1kJXnkO0nqxH6JXq-JRKS32JAnJC-jOsDJDnuS95_Bjny0FVTvRcXvoMXzuCWnqI_O3JnY4eYHeLsIJAFgdmQ6dqFsnS4qSK7I1ZwcHryhZ09ZOY=\nSignal: Freight / energy / labor costs cited as major headwind | Strength: MEDIUM | Weight: +1\nQuote: \"The weakening U.S. dollar is expected to have a negative impact of around 2% on ‍Lonza's sales and core earnings before interest, ​taxes, depreciation and amortisation (EBITDA) in 2026, the company said.\"\nDate: 2026-01-27 | Source: WTAQ | URL: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQElCYvdIa9Ni_tz84-emyiyZfkgAkYoPoW78dK83f7IuI1oJIBhLCU8UdUycJ_AAvCL-L-5Oo7bXWStGzzg1hrsy5r2YP6y6rNmgr846F0k97nl0NICYuzVLSR__Yj1ZZ6xnA52AgUACvBRJrWQuPza9KyVsp2TXXfFp6FVTGDtpTEgVPQ3zPrrPXtIb3WvrrCNp4O1agxmuj-SjcQHY94=\nSignal: Broad “efficiency / simplification / lean” initiatives repeated without quantified targets | Strength: MEDIUM | Weight: +1\nQuote: \"Lonza's CEO...stated, 'We are the pioneer and the world leader in the CDMO industry with cutting-edge science, smart technology, and lean manufacturing.'\"\nDate: 2026-02-03 | Source: Investing.com | URL: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGwudyuoZ2gzFvJia20ST262NSOblxJmjKhNsDqCcPpzu7pviCbDHllbAKTHlbSQ17OtK-jDwIPjevywa-juYuhy8P1Hp047ZTWQYA5z4MWku-_pqtReixyIddP8zyMyuRIgKi1kJXnkO0nqxH6JXq-JRKS32JAnJC-jOsDJDnuS95_Bjny0FVTvRcXvoMXzuCWnqI_O3JnY4eYHeLsIJAFgdmQ6dqFsnS4qSK7I1ZwcHryhZ09ZOY=\n\nSITUATION 3 — SIGNIFICANT GROWTH: LIKELY (7 pts)\nSignal: Major capacity expansion announced (new plant / lines / DC / automation ramp) | Strength: STRONG | Weight: +2\nQuote: \"Lonza plans to invest approximately CHF 500 million to upgrade the facility and enhance capabilities at the site to accommodate the next generation of mammalian biologics therapies\"\nDate: 2024-03-20 | Source: Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche | URL: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFpILhxmU-UalzEaOhisVkDeOLQMsY0VGd0zVQfvXPpfKCj-1iBcCw976aPt1CruX_7vGzdjy69HRTG4DXAyzAiKDlrFsrMvoHRfl5YZATVlQyvMP3IQrMJ8ogpxmfShdDL4POuOcY=\nSignal: M&A integration / carve-out execution program active | Strength: STRONG | Weight: +2\nQuote: \"The Vacaville large-scale mammalian drug substance facility was fully integrated into Lonza's global manufacturing network, securing additional commercial contracts and completing its first FDA audit under Lonza ownership.\"\nDate: 2026-01-28 | Source: PharmaSource | URL: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH8T1NXsTs4OG8WOm2u1kQsXU0-6ukzIjWJmFACTMbwNLjQP_Zoi6rW47hYp1OkolLjlSfPEaMxNSbT72sqMOVorX5Z-j8mI4eJtlbIN-tPs25V4DI8OmgHgmNY84em1J45IqNimmMMviBob4sa0waOx8F5BM-MwjeygsO7pMgXiv9_varVLq5ahwK4y5gg_p512Xxq8qVMPYVzp8o5oJ0u41SKBr1dgCvoqHY=\nSignal: Sustained high growth explicitly linked to scaling capacity and execution limits | Strength: MEDIUM | Weight: +1\nQuote: \"For 2026, Lonza anticipates a continued strong performance in line with its CDMO Organic Growth Model and expects CER sales growth of 11-12% and further CORE EBITDA margin expansion, reaching a level above 32% of sales.\"\nDate: 2026-01-28 | Source: Markets data | URL: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFECszmHkF_r1XDxGQ_7ZpSFHBzsrljBobFALDgCoBsUOZww0Rdj-bgHdgUONrlwR12HJ9X0KeAKaSd_5r8TZ66mrXEAjffiDmPZFM2DFKdoJCd-TOYJ9lY4T-A2crbQz9--VZXbHl2j-uj1sYTwUM82RQPT2N88bUAcXMGYE_02D8oN3kZTcKkS4-K720fp_CLjbsC2FpGcjRK3SMK06knkQ==\nSignal: Capex intensity rising (trend) consistent with growth narrative (no explicit project) | Strength: MEDIUM | Weight: +1\nQuote: \"With CHF 1.3 billion of CapEx in 2025 (19.6% of sales), Lonza made significant progress in executing its ongoing organic investment program to enable future growth across technologies\"\nDate: 2026-01-28 | Source: PharmaSource | URL: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEPlgUSulXsTzceTaA1xHcWWq4Ap6GZuZD5F_Pn-SdkWkCSv9kVRwYcfA_XGgLI_6gRXU5S7gWhwdRyq_KRWi84xdkqff7-AjWRi1-J6uKSyUI-c2r3NwnMqnhvxcaRbVAAJz6-b0lKFosOu-RSNlUXCu6Y4F_ia8e5VRcSRb8nwMKJwHVe68iKiVoHfy_O7rN371xD2zV46QIIkg-22Zg2Lm2gRsLKRBKLY_4=\nSignal: Service/backlog pressure explicitly due to demand growth | Strength: MEDIUM | Weight: +1\nQuote: \"Lonza reported strong 2025 results...Growth was driven by robust demand across key technology platforms and a better‑than‑expected contribution from the newly acquired Vacaville mammalian drug substance facility\"\nDate: 2026-01-27 | Source: TipRanks | URL: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH-RApW7drw3pqUA1Y5akmr6x-ycZLEMR-2g65C_2NGq1UixyjB6WP5TyTDHsCQi0QYmJG0Dowt9dGN7NwJqYU5AtqydP7Ifi8v6nW-f4f89fZM0BpksfqWOHEgD_0Fi05K_LAWPemwzk8J5QIdK37AKi04VN7mQwy7XAjKzXvQh8TOp4t8_NOW2rArTSvpLWInQZ7d6D5C1p-dOOUkenCE37OAxlyMdqto15-bGUgLAKGcV0yfIhIhlwUKFwiThRLo2b_5IVN46w==\n\nSITUATION 4 — SUPPLY CHAIN DISRUPTION: NOT PRESENT (0 pts)\nSignal: No evidence found within the last 12 months from allowed sources\n\nTOTAL SCORE: RC:3 | MP:6 | SG:7 | SCD:0 = 16/40\n",
    "table": "| Situation Status | Detected Signal | Evidence & Quote | Source & URL |\n|---|---|---|---|\n| Resource Constraints: UNCLEAR (3 pts) | Management explicitly states “resource constraints / lack of bandwidth / capacity shortage” (STRONG +2) | \"In exchange, we let our people own their careers.\" (Published: 2026-02-23) | ZipRecruiter — https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH-8HI-YjUdRAapdw1qWMq41nIoC1K1eN6-xDzhLv8rpQVXpXclt-MIu0RtlJDmFsBYkd2SlNxl9GBP3Y6NKCDSSRU3aQFkLvX_0XJJHF_VPwGt3lW2ioZSpAQ0-4Xq9riMjeNxAj7R8TucjtHMygNaLS_8pCemZb2rzCTNQOsa26dH4rKecd_60vpXe7zy-aE60YDQ_PQy0Lkxh3j3kTaG8SSi3Vs= |\n| | Persistent high volume of SC/Proc vacancies without urgency keywords (MEDIUM +1) | \"Planning and executing operational buying activities.\" (Published: 2025-10-24) | Lonza — https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHESHXkcYg60QPs6LXBjnVi7VecSQW5q6ooFJ2i_NOXUPnWp7HvD8hIQJbPXVlBrqi25yN5JItvdbEVQzQrbH9sXX91LqHQo6ymYQWT49TDn3AqyAm-Z58qOG2Rgge0uHP-i_WRvyDaAXdiDtF-u7wCvcjQcLlqZX_P1ku6u9rYuxbxzvi4r7oN78pIb0Hz |\n| Margin Pressure: LIKELY (6 pts) | Gross margin / EBITDA margin decline reported and discussed as structural (not one-off) (STRONG +2) | \"Lonza expects this margin to grow to more than 32% of sales in 2026.\" (Published: 2026-01-27) | WTAQ — https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQElCYvdIa9Ni_tz84-emyiyZfkgAkYoPoW78dK83f7IuI1oJIBhLCU8UdUycJ_AAvCL-L-5Oo7bXWStGzzg1hrsy5r2YP6y6rNmgr846F0k97nl0NICYuzVLSR__Yj1ZZ6xnA52AgUACvBRJrWQuPza9KyVsp2TXXfFp6FVTGDtpTEgVPQ3zPrrPXtIb3WvrrCNp4O1agxmuj-SjcQHY94= |\n| | Quantified cost-out / savings program (value + timeframe) (STRONG +2) | \"Lonza projects an 11-12% top-line growth in 2026 in constant currency, with a core EBITDA margin expected to exceed 32%.\" (Published: 2026-02-03) | Investing.com — https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGwudyuoZ2gzFvJia20ST262NSOblxJmjKhNsDqCcPpzu7pviCbDHllbAKTHlbSQ17OtK-jDwIPjevywa-juYuhy8P1Hp047ZTWQYA5z4MWku-_pqtReixyIddP8zyMyuRIgKi1kJXnkO0nqxH6JXq-JRKS32JAnJC-jOsDJDnuS95_Bjny0FVTvRcXvoMXzuCWnqI_O3JnY4eYHeLsIJAFgdmQ6dqFsnS4qSK7I1ZwcHryhZ09ZOY= |\n| | Freight / energy / labor costs cited as major headwind (MEDIUM +1) | \"The weakening U.S. dollar is expected to have a negative impact of around 2% on ‍Lonza's sales and core earnings before interest...\" (Published: 2026-01-27) | WTAQ — https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQElCYvdIa9Ni_tz84-emyiyZfkgAkYoPoW78dK83f7IuI1oJIBhLCU8UdUycJ_AAvCL-L-5Oo7bXWStGzzg1hrsy5r2YP6y6rNmgr846F0k97nl0NICYuzVLSR__Yj1ZZ6xnA52AgUACvBRJrWQuPza9KyVsp2TXXfFp6FVTGDtpTEgVPQ3zPrrPXtIb3WvrrCNp4O1agxmuj-SjcQHY94= |\n| | Broad “efficiency / simplification / lean” initiatives repeated without quantified targets (MEDIUM +1) | \"Lonza's CEO...stated, 'We are the pioneer and the world leader in the CDMO industry with cutting-edge science, smart technology, and lean manufacturing.'\" (Published: 2026-02-03) | Investing.com — https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGwudyuoZ2gzFvJia20ST262NSOblxJmjKhNsDqCcPpzu7pviCbDHllbAKTHlbSQ17OtK-jDwIPjevywa-juYuhy8P1Hp047ZTWQYA5z4MWku-_pqtReixyIddP8zyMyuRIgKi1kJXnkO0nqxH6JXq-JRKS32JAnJC-jOsDJDnuS95_Bjny0FVTvRcXvoMXzuCWnqI_O3JnY4eYHeLsIJAFgdmQ6dqFsnS4qSK7I1ZwcHryhZ09ZOY= |\n| Significant Growth: LIKELY* (7 pts) | Major capacity expansion announced (new plant / lines / DC / automation ramp) (STRONG +2) | \"Lonza plans to invest approximately CHF 500 million to upgrade the facility and enhance capabilities at the site...\" (Published: 2024-03-20) | Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche — https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFpILhxmU-UalzEaOhisVkDeOLQMsY0VGd0zVQfvXPpfKCj-1iBcCw976aPt1CruX_7vGzdjy69HRTG4DXAyzAiKDlrFsrMvoHRfl5YZATVlQyvMP3IQrMJ8ogpxmfShdDL4POuOcY= |\n| | M&A integration / carve-out execution program active (STRONG +2) | \"The Vacaville large-scale mammalian drug substance facility was fully integrated into Lonza's global manufacturing network...\" (Published: 2026-01-28) | PharmaSource — https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH8T1NXsTs4OG8WOm2u1kQsXU0-6ukzIjWJmFACTMbwNLjQP_Zoi6rW47hYp1OkolLjlSfPEaMxNSbT72sqMOVorX5Z-j8mI4eJtlbIN-tPs25V4DI8OmgHgmNY84em1J45IqNimmMMviBob4sa0waOx8F5BM-MwjeygsO7pMgXiv9_varVLq5ahwK4y5gg_p512Xxq8qVMPYVzp8o5oJ0u41SKBr1dgCvoqHY= |\n| | Sustained high growth explicitly linked to scaling capacity and execution limits (MEDIUM +1) | \"For 2026, Lonza anticipates a continued strong performance in line with its CDMO Organic Growth Model and expects CER sales growth of 11-12%...\" (Published: 2026-01-28) | Markets data — https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFECszmHkF_r1XDxGQ_7ZpSFHBzsrljBobFALDgCoBsUOZww0Rdj-bgHdgUONrlwR12HJ9X0KeAKaSd_5r8TZ66mrXEAjffiDmPZFM2DFKdoJCd-TOYJ9lY4T-A2crbQz9--VZXbHl2j-uj1sYTwUM82RQPT2N88bUAcXMGYE_02D8oN3kZTcKkS4-K720fp_CLjbsC2FpGcjRK3SMK06knkQ== |\n| | Capex intensity rising (trend) consistent with growth narrative (no explicit project) (MEDIUM +1) | \"With CHF 1.3 billion of CapEx in 2025 (19.6% of sales), Lonza made significant progress in executing its ongoing organic investment program...\" (Published: 2026-01-28) | PharmaSource — https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEPlgUSulXsTzceTaA1xHcWWq4Ap6GZuZD5F_Pn-SdkWkCSv9kVRwYcfA_XGgLI_6gRXU5S7gWhwdRyq_KRWi84xdkqff7-AjWRi1-J6uKSyUI-c2r3NwnMqnhvxcaRbVAAJz6-b0lKFosOu-RSNlUXCu6Y4F_ia8e5VRcSRb8nwMKJwHVe68iKiVoHfy_O7rN371xD2zV46QIIkg-22Zg2Lm2gRsLKRBKLY_4= |\n| | Service/backlog pressure explicitly due to demand growth (MEDIUM +1) | \"Lonza reported strong 2025 results...Growth was driven by robust demand across key technology platforms...\" (Published: 2026-01-27) | TipRanks — https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH-RApW7drw3pqUA1Y5akmr6x-ycZLEMR-2g65C_2NGq1UixyjB6WP5TyTDHsCQi0QYmJG0Dowt9dGN7NwJqYU5AtqydP7Ifi8v6nW-f4f89fZM0BpksfqWOHEgD_0Fi05K_LAWPemwzk8J5QIdK37AKi04VN7mQwy7XAjKzXvQh8TOp4t8_NOW2rArTSvpLWInQZ7d6D5C1p-dOOUkenCE37OAxlyMdqto15-bGUgLAKGcV0yfIhIhlwUKFwiThRLo2b_5IVN46w== |\n| Supply Chain Disruption: NOT PRESENT (0 pts) | No signals detected |  |  |\n"
  },
  "Givaudan": {
    "research": "SITUATION 1 — RESOURCE CONSTRAINTS: NOT PRESENT (0 pts)\nSignal: No evidence found within the last 12 months from allowed sources\n\nSITUATION 2 — MARGIN PRESSURE: LIKELY (6 pts)\nSignal: Gross margin / EBITDA margin decline reported and discussed as structural (not one-off) | Strength: STRONG | Weight: +2\nQuote: \"With higher input costs in 2025, including tariffs, the gross margin decreased to 43.5% in 2025 compared to 44.1% in 2024.\"\nDate: 2026-01-29 | Source: Givaudan | URL: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGzO05HSCD4OSSUbtGoCx4c-YsIG1foqM2WvMLbIK6enWtORhTNkR742ysqE_u2sqRwzyt31LmbzgTOHQC-DUDZqHRMgAtffoFFeIpykNmfgTApFNMyFQsOT29gCwbhvquRcZhJGUgkYHxVKE8BNZUuhqg0h39P5xz78dqsoSmem-xD84Q=\nSignal: Gross margin / EBITDA margin decline reported and discussed as structural (not one-off) | Strength: STRONG | Weight: +2\nQuote: \"The EBITDA margin was 23.4% in 2025 compared to 23.8% a year ago. On a comparable basis, the EBITDA margin decreased to 24.2% from 24.5% last year\"\nDate: 2026-01-29 | Source: Swissquote | URL: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEeffs4Scs9Ru1TtRsjZKfmx8Kv1bZXB6O9lvF7VsdUf2C2bDDLot3lmO8mUA_DecOStMFFM6CEY6MYmen6c684ITw4qkjB3FuTVpQD4JwIa9ATkhb0xjUSlEpwca9KOFucX3jwUIyg8RpulGFTdgJsz36DeZ0Xjo4R0PUdtQ=\nSignal: Input costs / inflation described as headwind without quantified structural margin impact | Strength: MEDIUM | Weight: +1\nQuote: \"However, the group disappointed on its EBITDA margin, which, although still high, fell to 24.2% from 24.5% in 2024, weighed down by negative currency effects and “higher raw material costs” due to customs duties\"\nDate: 2026-01-30 | Source: Premium Beauty News | URL: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEwgEpgOZAOFFgwjjyPkW7Ud5Lpi2F6HvYeCbBnTKY8wmNHeepOLwSOA6p7KOL1haf3h9ixsU4Owe6pWwvcz_wKVEaoa3BCSO84ErpAN5f7uLnkIHB7IMfPwjAN0T0XZrbO89HvnpMAWBapYV3BGj6YiS3aVBDGtbyS0ICEDydbEEpzL3skA7A=\nSignal: Freight / energy / labor costs cited as major headwind | Strength: MEDIUM | Weight: +1\nQuote: \"On Thursday, January 29, Swiss group Givaudan published mixed annual results, hampered in particular by US customs duties.\"\nDate: 2026-01-30 | Source: Premium Beauty News | URL: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEwgEpgOZAOFFgwjjyPkW7Ud5Lpi2F6HvYeCbBnTKY8wmNHeepOLwSOA6p7KOL1haf3h9ixsU4Owe6pWwvcz_wKVEaoa3BCSO84ErpAN5f7uLnkIHB7IMfPwjAN0T0XZrbO89HvnpMAWBapYV3BGj6YiS3aVBDGtbyS0ICEDydbEEpzL3skA7A=\n\nSITUATION 3 — SIGNIFICANT GROWTH: LIKELY (6 pts)\nSignal: Major capacity expansion announced (new plant / lines / DC / automation ramp) | Strength: STRONG | Weight: +2\nQuote: \"Givaudan invests CHF 187 million (US$233.6 million) in a new liquid production facility in Ohio, with completion expected in 18 months.\"\nDate: 2025-10-08 | Source: Food Ingredients First | URL: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGWPOB7LFh1mmhfKB1TFnmC2qLZHUYLRFkh3wb9V2Z0--ZjGxE9HA2kzBhELbQCDcn6IkS0Mcq_zM-eTVDVoMgMboUYUXmt8ZDnActZXlZBKWVq0yS8us-X0I8WTwzkhX_ofEQTpf1sVZKVYcO02IQ5hjX_6oImOMhltDPNxQpzo1Bj9wle9e6DLPThwgZZ\nSignal: Major capacity expansion announced (new plant / lines / DC / automation ramp) | Strength: STRONG | Weight: +2\nQuote: \"Givaudan, the global leader in Fragrance & Beauty, today announced a significant strategic investment to build a new fragrances manufacturing facility in Pedro Escobedo\"\nDate: 2026-02-03 | Source: Givaudan | URL: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH68agHu2iOkVqUriGSped6Q_uhLoQi-YZg8q5YIdvm0adoljc2fdSAjXO6j-UOhxQZ-MSPzacxbnXw8EOiuxqeFXIv0z9cKQEUsGjSmDdUFThSFGEoM0jAABEMZd2SviNy3cT9nz5-JzJMaE0hPi-cgGvTBD_9bRutklIV38RRj9zDf0AThCPPBzkRj7iX7hkv1eiJonZoxnKuSDHf_A06bYJBy12fdgTDqE0C7daNuBhuKi4=\nSignal: Acquisition integration / carve-out execution program active | Strength: MEDIUM | Weight: +1\nQuote: \"Givaudan announced its intention to acquire Belle Aire Creations, a prominent US-based fragrance house known for its creative expertise and strong regional customer relationships. The acquisition was completed in December 2025.\"\nDate: 2026-02-24 | Source: Givaudan | URL: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH5mr7NhZXEpVBxrPMERlFs3cMIapBGtP7F7he-VtnyBJKtmSN7v72DQD_-JXx4VH647pcFPUJAmMbHiyhfsu-o0EJPMqaab-XKYchwU-RU2GOLBhR_oE7ZFwvKFW2yeuvMjCXqc_2_4ssStPAmz7M7FKACqsxynR5fpXg13fxzXTOe9Niq6OxNEG44xYuOWFeR4A==\nSignal: New supplier onboarding / manufacturing partnerships due to growth | Strength: MEDIUM | Weight: +1\nQuote: \"Givaudan announced the intention to acquire a majority stake in Vollmens Fragrances as part of its 2025 strategy to grow with local and regional customers. The acquisition was completed in September 2025.\"\nDate: 2026-02-24 | Source: Givaudan | URL: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH5mr7NhZXEpVBxrPMERlFs3cMIapBGtP7F7he-VtnyBJKtmSN7v72DQD_-JXx4VH647pcFPUJAmMbHiyhfsu-o0EJPMqaab-XKYchwU-RU2GOLBhR_oE7ZFwvKFW2yeuvMjCXqc_2_4ssStPAmz7M7FKACqsxynR5fpXg13fxzXTOe9Niq6OxNEG44xYuOWFeR4A=\n\nSITUATION 4 — SUPPLY CHAIN DISRUPTION: NOT PRESENT (0 pts)\nSignal: No evidence found within the last 12 months from allowed sources\n\nTOTAL SCORE: RC:0 | MP:6 | SG:6 | SCD:0 = 12/40\n",
    "table": "| Situation Status | Detected Signal | Evidence & Quote | Source & URL |\n|---|---|---|---|\n| Resource Constraints: NOT PRESENT (0 pts) | No signals detected | No signals detected | No signals detected |\n| Margin Pressure: LIKELY* (6 pts) | Gross margin / EBITDA margin decline reported and discussed as structural (not one-off) (STRONG +2) | \"With higher input costs in 2025, including tariffs, the gross margin decreased to 43.5% in 2025 compared to 44.1% in 2024.\" (Published: 2026-01-29) | Givaudan — https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGzO05HSCD4OSSUbtGoCx4c-YsIG1foqM2WvMLbIK6enWtORhTNkR742ysqE_u2sqRwzyt31LmbzgTOHQC-DUDZqHRMgAtffoFFeIpykNmfgTApFNMyFQsOT29gCwbhvquRcZhJGUgkYHxVKE8BNZUuhqg0h39P5xz78dqsoSmem-xD84Q= |\n| | Gross margin / EBITDA margin decline reported and discussed as structural (not one-off) (STRONG +2) | \"The EBITDA margin was 23.4% in 2025 compared to 23.8% a year ago. On a comparable basis, the EBITDA margin decreased to 24.2% from 24.5% last year\" (Published: 2026-01-29) | Swissquote — https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEeffs4Scs9Ru1TtRsjZKfmx8Kv1bZXB6O9lvF7VsdUf2C2bDDLot3lmO8mUA_DecOStMFFM6CEY6MYmen6c684ITw4qkjB3FuTVpQD4JwIa9ATkhb0xjUSlEpwca9KOFucX3jwUIyg8RpulGFTdgJsz36DeZ0Xjo4R0PUdtQ= |\n| | Input costs / inflation described as headwind without quantified structural margin impact (MEDIUM +1) | \"However, the group disappointed on its EBITDA margin, which, although still high, fell to 24.2% from 24.5% in 2024, weighed down by negative currency effects and “higher raw material costs” due to customs duties\" (Published: 2026-01-30) | Premium Beauty News — https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEwgEpgOZAOFFgwjjyPkW7Ud5Lpi2F6HvYeCbBnTKY8wmNHeepOLwSOA6p7KOL1haf3h9ixsU4Owe6pWwvcz_wKVEaoa3BCSO84ErpAN5f7uLnkIHB7IMfPwjAN0T0XZrbO89HvnpMAWBapYV3BGj6YiS3aVBDGtbyS0ICEDydbEEpzL3skA7A= |\n| | Freight / energy / labor costs cited as major headwind (MEDIUM +1) | \"On Thursday, January 29, Swiss group Givaudan published mixed annual results, hampered in particular by US customs duties.\" (Published: 2026-01-30) | Premium Beauty News — https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEwgEpgOZAOFFgwjjyPkW7Ud5Lpi2F6HvYeCbBnTKY8wmNHeepOLwSOA6p7KOL1haf3h9ixsU4Owe6pWwvcz_wKVEaoa3BCSO84ErpAN5f7uLnkIHB7IMfPwjAN0T0XZrbO89HvnpMAWBapYV3BGj6YiS3aVBDGtbyS0ICEDydbEEpzL3skA7A= |\n| Significant Growth: LIKELY (6 pts) | Major capacity expansion announced (new plant / lines / DC / automation ramp) (STRONG +2) | \"Givaudan invests CHF 187 million (US$233.6 million) in a new liquid production facility in Ohio, with completion expected in 18 months.\" (Published: 2025-10-08) | Food Ingredients First — https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGWPOB7LFh1mmhfKB1TFnmC2qLZHUYLRFkh3wb9V2Z0--ZjGxE9HA2kzBhELbQCDcn6IkS0Mcq_zM-eTVDVoMgMboUYUXmt8ZDnActZXlZBKWVq0yS8us-X0I8WTwzkhX_ofEQTpf1sVZKVYcO02IQ5hjX_6oImOMhltDPNxQpzo1Bj9wle9e6DLPThwgZZ |\n| | Major capacity expansion announced (new plant / lines / DC / automation ramp) (STRONG +2) | \"Givaudan, the global leader in Fragrance & Beauty, today announced a significant strategic investment to build a new fragrances manufacturing facility in Pedro Escobedo\" (Published: 2026-02-03) | Givaudan — https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH68agHu2iOkVqUriGSped6Q_uhLoQi-YZg8q5YIdvm0adoljc2fdSAjXO6j-UOhxQZ-MSPzacxbnXw8EOiuxqeFXIv0z9cKQEUsGjSmDdUFThSFGEoM0jAABEMZd2SviNy3cT9nz5-JzJMaE0hPi-cgGvTBD_9bRutklIV38RRj9zDf0AThCPPBzkRj7iX7hkv1eiJonZoxnKuSDHf_A06bYJBy12fdgTDqE0C7daNuBhuKi4= |\n| | Acquisition integration / carve-out execution program active (MEDIUM +1) | \"Givaudan announced its intention to acquire Belle Aire Creations, a prominent US-based fragrance house known for its creative expertise and strong regional customer relationships. The acquisition was completed in December 2025.\" (Published: 2026-02-24) | Givaudan — https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH5mr7NhZXEpVBxrPMERlFs3cMIapBGtP7F7he-VtnyBJKtmSN7v72DQD_-JXx4VH647pcFPUJAmMbHiyhfsu-o0EJPMqaab-XKYchwU-RU2GOLBhR_oE7ZFwvKFW2yeuvMjCXqc_2_4ssStPAmz7M7FKACqsxynR5fpXg13fxzXTOe9Niq6OxNEG44xYuOWFeR4A== |\n| | New supplier onboarding / manufacturing partnerships due to growth (MEDIUM +1) | \"Givaudan announced the intention to acquire a majority stake in Vollmens Fragrances as part of its 2025 strategy to grow with local and regional customers. The acquisition was completed in September 2025.\" (Published: 2026-02-24) | Givaudan — https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH5mr7NhZXEpVBxrPMERlFs3cMIapBGtP7F7he-VtnyBJKtmSN7v72DQD_-JXx4VH647pcFPUJAmMbHiyhfsu-o0EJPMqaab-XKYchwU-RU2GOLBhR_oE7ZFwvKFW2yeuvMjCXqc_2_4ssStPAmz7M7FKACqsxynR5fpXg13fxzXTOe9Niq6OxNEG44xYuOWFeR4A= |\n| Supply Chain Disruption: NOT PRESENT (0 pts) | No signals detected | No signals detected | No signals detected |\n"
  }
}